SP Group (SPG) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
25 Mar, 2026Executive summary
Achieved record Q4 2025 performance, with revenue up nearly 14% and EBITDA up 26% in the quarter, demonstrating resilience despite project postponements and global uncertainties.
Full-year revenue grew 0.9% to DKK 2,948 million, with EBITDA margin at 20.2% and EBT margin at 11.7%.
Acquired Idé-Pro in December 2025 for DKK 700 million, expected to contribute DKK 450 million in revenue and DKK 100 million in EBITDA, with synergies of DKK 20-25 million by 2027.
Expanded U.S. healthcare production with Atlanta factory operational since January 2025 and increased activity in India.
Subcontracting work grew almost 6%, while revenue from own products declined by 10% due to project postponements.
Financial highlights
Revenue: DKK 2,948 million (+0.9% year-over-year).
EBITDA: DKK 595 million (+1.1% year-over-year), margin 20.2%.
EBT: DKK 345 million (+0.1% year-over-year), EBT margin 11.7%.
Earnings per share, diluted, rose by 2.3% to DKK 22.1.
Cash flow from operations: DKK 393 million, down DKK 117 million due to increased inventory.
Outlook and guidance
2026 revenue growth expected at 15%-23%, EBITDA margin 19%-21%, EBT margin 11%-13%.
Growth driven by new products, customers, and Idé-Pro acquisition (approx. 15% of growth).
Assumes Middle East conflict de-escalates soon; risks from raw material and energy prices acknowledged.
Long-term ambition: revenue growth 6%-9% annually to DKK 4.5 billion by 2030, EBT margin 12%-14%.
Latest events from SP Group
- Record H1 2026 growth and UK expansion led to upgraded outlook and strong margins.SPG
Q2 2026 - Record H1 2026 revenue and earnings growth led to an upgraded full-year outlook.SPG
Q2 2026 - Record Q1 2026 growth, robust outlook, and active capital returns amid global uncertainty.SPG
Q1 2026 - Record Q1 2026 revenue and profit growth, outlook and guidance remain robust.SPG
Q1 2026 - Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 2025 - H1 2025 saw lower revenue and earnings, but margin guidance and growth projects remain on track.SPG
Q2 2025 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 2024 - Q1 2025 delivered 8.8% revenue growth and margin expansion, with outlook unchanged.SPG
Q1 2025 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 2024